Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 3/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.32 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.31 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3349296 | 0.81 | CYP2D6 (0.40) | — | |
| Hydrochloric Acid SCHEMBL10986629 | 0.80 | CA12 (0.32) | KDM4C | |
| SCHEMBL20311081 | 0.80 | CAPN9 (0.33) | KDM4CKDM4APHF8KDM2ASMN1; SMN2 | |
| SCHEMBL20908859 | 0.70 | CNR1 (0.33) | KDM4CKDM4APHF8KDM2AL3MBTL1 | |
| SCHEMBL1859590 | 0.70 | KDM4C (0.38) | KDM4CKDM4APHF8KDM2A | |
| SCHEMBL4774192 | 0.67 | KDM4C (0.32) | KDM4CHDAC1HDAC2 | |
| SCHEMBL5439829 | 0.66 | CYP2D6 (0.41) | RAB9ACNR1LMNA | |
| SCHEMBL28059470 | 0.64 | CA12 (0.32) | PHF8KDM2ARAB9A | |
| SCHEMBL1978560 | 0.64 | ALDH1A1 (0.35) | KDM4CKDM4APHF8KDM2A | |
| SCHEMBL3660208 | 0.63 | CA1 (0.34) | RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334677-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2010022076-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-7498436-B2 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-03-03 | — | — | US | disclosed |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
| US-7176242-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20060106256-A1 | Substituted hydroxyethylamines | PHARMACIA & UPJOHN COMPANY | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | KDM4C 2130/4885KDM4A 2071/4885PHF8 3102/4885 |
| US-20060106256-A1 | Substituted hydroxyethylamines | HNMT, PNMT, BCHE | KDM4C 265/4885KDM4A 221/4885PHF8 235/4885 |
| US-20070213316-A1 | Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease | BACE1, BACE2, APP | KDM4C 4360/4885KDM4A 4325/4885PHF8 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.